Download presentation
Presentation is loading. Please wait.
1
Volume 49, Issue 5, Pages 781-789 (May 2006)
Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasentan Influence Quality of Life? David Cella, Daniel P. Petrylak, Mayer Fishman, Chris Teigland, Jay Young, Parvez Mulani European Urology Volume 49, Issue 5, Pages (May 2006) DOI: /j.eururo Copyright © 2006 Elsevier B.V. Terms and Conditions
2
Fig. 1 Time to disease progression in atrasentan trials: Data are shown from the meta-analysis (studies M and M96-594) intent-to-treat population and from the intent-to-treat and evaluable populations in a phase II trial (study M96-594) and a phase III trial (study M00-211). Data are presented as hazard ratio with 95% confidence intervals. ITT=intent-to-treat. European Urology , DOI: ( /j.eururo ) Copyright © 2006 Elsevier B.V. Terms and Conditions
3
Fig. 2 Mean QOL treatment difference between patients in the placebo group and 10mg atrasentan group using analysis of covariance. Data are shown from the meta-analysis as mean difference with 95% confidence intervals. QOL=Quality of Life. European Urology , DOI: ( /j.eururo ) Copyright © 2006 Elsevier B.V. Terms and Conditions
4
Fig. 3 Quality-adjusted time to disease progression for FACT-P and EORTC QLQ C-30 domains. In this phase III trial, patients were randomized to once-daily atrasentan 10mg or placebo and treated until disease progression. Data are presented as hazard ratio with 95% confidence intervals. FACT-P=Functional Assessment of Cancer Therapy-Prostate; PCS=Prostate Cancer Subscore; EORTC=European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). European Urology , DOI: ( /j.eururo ) Copyright © 2006 Elsevier B.V. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.